Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEA CAR-T cells (China Medical University)
- Development stage
- Unknown
- Lead developer
- China Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CEA CAR-T cells (China Medical University) is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting Carcinoembryonic Antigen (CEA), also known as CEACAM5. CEA is a cell-surface glycoprotein that is overexpressed in a variety of solid tumors, particularly those of the gastrointestinal tract, such as colorectal, pancreatic, and gastric cancers. The therapy involves the ex vivo genetic modification of a patient's peripheral blood mononuclear cells (PBMCs) to express a CAR that recognizes CEA. Upon re-infusion into the patient following lymphodepleting chemotherapy, these engineered T cells are designed to specifically bind to CEA-expressing tumor cells, leading to T-cell activation, proliferation, and the subsequent lysis of the cancer cells. This candidate is currently being investigated in a Phase 1 clinical trial for patients with CEA-positive locally advanced or metastatic solid tumors.
- Other names
- anti-CEA-CAR-T cell injectionanti-CEA-CAR-T cellsIntravenous infusion anti-CEA-CAR-T cell
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on anti-CEA CAR-T cells (China Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEA CAR-T cells (China Medical University).